Abstract

AimsWomen with heart failure are typically older, and more often have hypertension and a preserved left ventricular ejection fraction as compared with men. We sought to analyze if these sex differences influence the course and outcome of acute heart failure.Methods and resultsWe analyzed sex differences in acute heart failure in 1161 patients enrolled in the RELAX-AHF study. The pre-specified study endpoints were used. At baseline, women (436/1161 patients) were older, had a higher left ventricular ejection fraction, a higher rate of hypertension, and were treated differently from men. Early dyspnea improvement (moderate or marked dyspnea improvement measured by Likert scale during the first 24 h) was greater in women. However, dyspnea improvement over the first 5 days (change from baseline in the visual analog scale area under the curve (VAS AUC) to day 5) was similar between men and women. Women reported greater improvements in general wellbeing by Likert, but no such benefits were evident with the VAS score. Multi-variable predictors of moderate or marked dyspnea improvement were female sex (p = 0.0011), lower age (p = 0.0026) and lower diuretic dose (p = 0.0067). The additional efficacy endpoints of RELAX-AHF were similar between men and women and serelaxin was equally effective in men and women.ConclusionsWomen exhibit better earlier dyspnea relief and improvement in general wellbeing compared with men, even adjusted for age and left ventricular ejection fraction. However, in-hospital and post-discharge clinical outcomes were similar between men and women.This trial is registered at ClinicalTrials.gov, NCT00520806.

Highlights

  • Women and men show marked differences both in the onset of heart failure and in established chronic heart failure [1, 2]

  • We analyzed sex differences in acute heart failure in 1161 patients enrolled in the RELAX-AHF study

  • The additional efficacy endpoints of RELAX-AHF were similar between men and women and serelaxin was effective in men and women

Read more

Summary

Introduction

Women and men show marked differences both in the onset of heart failure and in established chronic heart failure [1, 2]. We recently showed that clinical characteristics of men and women admitted for acute heart failure. No studies have focused on differences in dyspnea relief and changes in general wellbeing between men and women admitted for acute heart failure. We investigate sex differences in early and persistent dyspnea relief as well as additional efficacy endpoints, and analyzed patient features and heart failure characteristics in men and women hospitalized for acute heart failure enrolled in the RELAX-AHF study [5]. The RELAX-AHF study tested the effects of serelaxin, a recombinant form of the natural hormone human relaxin 2, vs placebo on dyspnea relief on top of standard of care [5], and provided insights into specific effects of serelaxin in acute heart failure [6, 7]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call